Integrin-linked kinase: a cancer therapeutic target unique among its ILK

By G. Hannigan, A. Troussard, S. Dedhar. Nature Reviews. Cancer, 2005

619 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Signaling mechanisms of the epithelial-mesenchymal transition (2014, background): “TGF-β signaling can directly increase LEF1 expression through SMADs and inhibit glycogen synthase kinase 3β (GSK-3β) through the phosphoinositide 3-kinase (PI3K)–Akt pathway, which enables β-catenin–dependent activation of LEF-1 to induce EMT (58, 105).”
ILK, PINCH and parvin: the tIPP of integrin signalling (2006, background): “Interestingly, ILK expression is upregulated in many human tumour”
Integrin signalling at a glance (2009, background): “ILK contains an N-terminal ankyrin-repeat domain that mediates protein interactions with PINCH1 or PINCH2, and a Cterminal kinase domain that supports interactions with α-, β- or γ-parvin, paxillin (see below) and, possibly, βintegrin tails (Hannigan et al., 2005; Legate et al., 2006).”